RxDoctor Payments Data

Martha Eskridge

Women's Health · Foley, ALNPI 1942592308

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Mayne Pharma Commercial LLC at 34.0% of the total.

$820in general payments, 2019–2025

Across 35 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$279
  • AbbVie$196
  • Bayer$49
  • BD$45
  • Therapeuticsmd, Inc.$44
  • Lilly USA, LLC$39
  • plus $167 from 9 others

What the payments were for

  • Food & beverage$820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$820 in reported general payments places this provider in the 60th percentile of 107 women's health providers in Alabama.

See all women's health providers in Alabama

Medicare billing

Part B allowed, 2024
$9,165
Medicare patients
108
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron23$13,876
Estradiol216$8,408
Estradiol (Twice Weekly)Estradiol22$2,832
ProgesteroneProgesterone, Micronized45$2,356
Medroxyprogesterone Acetate46$1,803
Estradiol (Once Weekly)Estradiol15$1,369
ValacyclovirValacyclovir Hcl20$911
Norethindrone Acetate20$740
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$702
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$301
Fluconazole39$267
Venlafaxine Hcl ErVenlafaxine Hcl16$207
Metronidazole14$74
Metformin Hcl24$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$23$13,87623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 107 women's health providers in Alabama.

Other women's health in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →